Evidence map›Paper›PMID 31501975›Full record

Observational studyJournal of neurology2019

How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study.

Carlo Colosimo, David Charles, Vijay P Misra, Pascal Maisonobe, Savary Om, INTEREST IN CD2 study group

Erratum issued Registry-linked trialOpen access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01753349 (An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01753349 completednot on this map

An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact

TypeobservationalSponsorIpsenRan2012 to 2017Enrolled1,050ConditionsCervical DystoniaArmsBotulinum toxin type A
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Mental health and quality of life in patients with cervical dystonia.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 4 countries.

Carlo ColosimoDepartment of Neurology, Santa Maria University Hospital, Viale Tristano di Joannuccio 1, 05100, Terni, Italy. carlo.colosimo@uniroma1.it.ORCID http://orcid.org/0000-0002-2216-3973
David CharlesDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
Vijay P MisraDepartment of Neurology, Imperial College Healthcare NHS Trust, London, UK.
Pascal MaisonobeIpsen Pharma, Boulogne-Billancourt, France.
Savary OmIpsen Pharma, Boulogne-Billancourt, France.
INTEREST IN CD2 study group
Imperial College Healthcare NHS Trust · GBIpsen (France) · FRSanta Maria Nuova Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with cervical dystonia (CD) typically require regular injections of botulinum toxin to maintain symptomatic control. We aimed to document long-term patient satisfaction with CD symptom control in a large cohort of patients treated in routine practice.

methodsThis was a prospective, international, observational study (NCT01753349) following the course of adult CD treated with botulinum neurotoxin type A (BoNT-A) over 3 years. A comprehensive clinical assessment status was performed at each injection visit and subjects reported satisfaction in two ways: satisfaction with symptom control at peak effect and at the end of treatment cycle.

resultsSubject satisfaction remained relatively stable from the first to the last injection visit. At 3 years, 89.9% of subjects reported satisfaction with symptom control at peak effect and 55.6% reported satisfaction with symptom control at end of treatment cycle. By contrast, objective ratings of CD severity showed an overall reduction over 3 years. Mean ± SD Toronto Western Spasmodic Rating Scale (TWSTRS) Total scores (clinician assessed at end of treatment cycle) decreased from 31.59 ± 13.04 at baseline to 24.49 ± 12.43 at 3 years (mean ± SD reduction from baseline of - 6.97 ± 11.56 points). Tsui scale scores also showed gradual improvement; the percent of subjects with a tremor component score of 4 reduced from 12.4% at baseline to 8.1% at 3 years.

conclusionsDespite objective clinical improvements over 3 years, subject satisfaction with symptom control remained relatively constant, indicating that factors other than symptom control also play a role in patient satisfaction.

Indexed as

Patient SatisfactionAdolescentAdultAgedBotulinum Toxins, Type AFemaleHumansMaleMiddle AgedNeuromuscular AgentsOutcome Assessment, Health CareProspective StudiesTorticollisYoung AdultBotulinum Toxins, Type ANeuromuscular AgentsBotulinum toxinCervical dystoniaObservational studySatisfactionTreatment

Identifiers

PMID31501975
PMCPMC6851034
OpenAlexW2972824809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.